Cemiplimab combined with chemotherapy chemotherapy in advanced non-small cell lung cancer: an updated EMPOWER-Lung 3 trial-based cost-effectiveness analysis by Gaofeng Zhu, Hongfu Cai, Zhiwei Zheng

Get full text

Preoperative Prognostic Nutritional Index Predict Survival in Patients With Resectable Esophageal Squamous Cell Carcinoma by Zhiwei Zheng, Huide Zhu, Hongfu Cai

Get full text

Cost-effectiveness analysis of pembrolizumab in combination with chemotherapy compared with chemotherapy alone as first-line treatment for patients with advanced biliary tract canc... by Zhiwei Zheng, Ling Fang, Hongfu Cai

Get full text

Cost-effectiveness analysis of serplulimab combination therapy versus chemotherapy alone for patients with extensive-stage small cell lung cancer by Zhiwei Zheng, Hongcai Chen, Hongfu Cai

Get full text

First-line treatment with durvalumab plus chemotherapy versus chemotherapy alone for metastatic non-small-cell lung cancer in the USA: a cost-effectiveness analysis by Ling Fang, Zhiwei Zheng, Hongfu Cai

Get full text

Cost-effectiveness analysis of sugemalimab vs. chemotherapy as first-line treatment of metastatic nonsquamous non-small cell lung cancer by Zhiwei Zheng, Huide Zhu, Ling Fang, Hongfu Cai

Get full text

Tislelizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis by Zhiwei Zheng, Yuxuan Lin, Yuxuan Lin, Hongfu Cai

Get full text

Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy vs. Chemotherapy Alone as First-Line Treatment in Patients With Esophageal Squamous Cell Carcinoma and PD-L1 CPS of 1... by Zhiwei Zheng, Jingrong Lin, Huide Zhu, Hongfu Cai

Get full text

Cost-Effectiveness Analysis of Olaparib Maintenance Treatment for Germline BRCA-Mutated Metastatic Pancreatic Cancer by Na Li, Na Li, Huanrui Zheng, Huanrui Zheng, Yanlei Huang, Bin Zheng, Bin Zheng, Hongfu Cai, Hongfu Cai, Maobai Liu, Maobai Liu

Get full text

Cost-Utility Analysis of Camrelizumab Plus Chemotherapy Versus Chemotherapy Alone as a First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer in China by Ting Chen, Ruixiang Xie, Qiuling Zhao, Hongfu Cai, Lin Yang

Get full text

First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis by Longfeng Zhang, Yongfu Hang, Maobai Liu, Na Li, Hongfu Cai

Get full text

Cost-effectiveness analysis of lenvatinib plus pembrolizumab compared with chemotherapy for patients with previously treated mismatch repair proficient advanced endometrial cancer... by Zhiwei Zheng, Liu Yang, Siqi Xu, Huide Zhu, Hongfu Cai

Get full text

First-line nivolumab plus ipilimumab or chemotherapy chemotherapy alone for advanced esophageal cancer: a cost-effectiveness analysis by Xueqiong Cao, Hongfu Cai, Na Li, Bin Zheng, Zhiwei Zheng, Maobai Liu

Get full text

Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma by Hongfu Cai, Baohua Xu, Na Li, Bin Zheng, Zhiwei Zheng, Maobai Liu

Get full text

Cost-effectiveness analysis of nivolumab plus ipilimumab chemotherapy as the first-line treatment for unresectable malignant pleural mesothelioma by Liu Yang, Xueqiong Cao, Na Li, Bin Zheng, Maobai Liu, Hongfu Cai

Get full text

Cost-effectiveness analysis of elacestrant versus standard endocrine therapy for second-/third-line treatment of patients with HR+/HER2- advanced or metastatic breast cancer: a US... by Wanxian Zeng, Wanxian Zeng, Xueqiong Cao, Xueqiong Cao, Jingwen Lin, Jingwen Lin, Bin Zheng, Bin Zheng, Na Li, Na Li, Maobai Liu, Maobai Liu, Hongfu Cai, Hongfu Cai

Get full text

Efficacy and safety of adding bevacizumab biosimilar or original drug to platinum-based chemotherapy as first-line treatment in patients with advanced NSCLC: a systematic review an... by Liu Yang, Maobai Liu, Xueqiong Cao, Na Li, Bin Zheng, Jianhao Deng, Hongfu Cai

Get full text

First-line nivolumab plus chemotherapy chemotherapy alone for advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma: a cost-effectiveness analys... by Xueqiong Cao, Mingming Zhang, Na Li, Bin Zheng, Maobai Liu, Xiaobing Song, Hongfu Cai

Get full text

Cost-effectiveness analysis of axicabtagene ciloleucel as a second-line treatment for diffuse large B-cell lymphoma in China and the United States by Na Li, Jianying Lei, Jiahao Zhang, Hongfu Cai, Bin Zheng, Ting Yang, Maobai Liu, Jianda Hu

Get full text

Mehran 2 Contrast-Associated Acute Kidney Injury Risk Score: Is it Applicable to the Asian Percutaneous Coronary Intervention Population? by Ying Guo MD, Xue Xu MD, Yunjing Xue MD, Chunling Zhao MD, Xiaohong Zhang MD, Hongfu Cai MD

Get full text